Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

Boehringer spends €1.18bn to acquire NBE-Therapeutics

Company specialises in antibody-drug conjugate development

- PMLiVE

FDA expert panel recommends EUA for Pfizer/BioNTech COVID-19 vaccine

Formal approval in the US could follow 'within days'

Strategies to Launch and Commercialize Healthcare Innovations

Dr. Roxie Mooney, Healthcare Commercialization Strategist at Legacy DNA and best-selling author, joins Natalie Yeadon, Co-owner & Managing Director at Impetus Digital. We are discussing all things healthcare innovation and commercialization,...

Impetus Digital

Patient-Centered Digital Transformation

Lygeia Ricciardi, Advisor at Carium, joins Natalie Yeadon, Co-Founder & CEO at Impetus Digital in this Fireside Chat. They explore a variety of topics related to patient-centric care, digital health transformation,...

Impetus Digital

Effects of the Pandemic on Evidence Generation & Scientific Exchange

Farah Husein, Director, Evidence Generation, Canadian Centre of Excellence, at Takeda, discusses all things evidence generation, including the impact of the COVID-19 pandemic on HEOR, RWE, epidemiology, and PRO studies and...

Impetus Digital

Press release: InSite Event™ named one of the most innovative services of 2020

Press ReleaseContact: Jess Masciangelo, Business Development Directorjmasciangelo@impetusdigital.commeetwithimpetus.comINSITE EVENT™ NAMED ONE OF THE MOST INNOVATIVE SERVICES OF 2020Toronto, ON, December 10, 2020 — Impetus Digital’s new virtual event platform InSite Event™...

Impetus Digital

- PMLiVE

Advance Outcomes named of the most innovative strategies of 2020 by PM360

PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has named Lucid Group’s pioneering behaviour-change methodology, Advance OutcomesTM, as one of...

Lucid Group Communications Limited

- PMLiVE

J&J trims the size of its phase 3 COVID-19 vaccine trial

Company cuts size of participant population from 60,000 to 40,000

- PMLiVE

Canada joins UK in approving Pfizer/BioNTech COVID-19 vaccine

Health Canada will continue to monitor safety of jab

- PMLiVE

UK regulator warns of allergic reactions to Pfizer/BioNTech vaccine

New MHRA guidance comes after reports of allergic reactions to COVID-19 vaccine

- PMLiVE

ASH 2020: Gilead eyes new Yescarta indication, Vertex/CRISPR make headway in sickle cell and more

A round-up of some of the key data from the annual American Society of Hematology (ASH) meeting

- PMLiVE

FDA briefing document paves the way for Pfizer/BioNTech COVID-19 vaccine approval

Advisory Committee is set to meet today to discuss vaccine's safety and efficacy data

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links